A Single-Center, Double-Blinded, Placebo-Controlled, Phase 1 Evaluation of the Safety of Ragweed Mix Given in Four Monthly Doses by Intralymphatic Node Injections for Inducing Tolerance in Subjects With Ragweed Induced Allergic Conjunctivitis and Allergic Rhinitis

Trial Profile

A Single-Center, Double-Blinded, Placebo-Controlled, Phase 1 Evaluation of the Safety of Ragweed Mix Given in Four Monthly Doses by Intralymphatic Node Injections for Inducing Tolerance in Subjects With Ragweed Induced Allergic Conjunctivitis and Allergic Rhinitis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2017

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary)
  • Indications Allergic conjunctivitis; Allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Woodmont Pharmaceuticals
  • Most Recent Events

    • 22 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 07 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top